Uncategorized

iCubate announces leadership change

June 17,  2020 Huntsville, Alabama Today, iCubate board chairman Jian Han announced a change in leadership of the company. Carter Wells, chief executive officer since 2010, will move into a consulting role and veteran biotech executive Dennis Grimaud will join the company as chief executive. “I would like to thank...

Read more
iCubate Weekly Digest April 26, 2020

iCubate Weekly Digest April 26, 2020

As businesses begin to re-open in cities and states around the country, all of us at iCubate remind and encourage you to follow the advice of trusted institutions and leaders. Here is a link to the CDC’s COVID19 site for the latest information. Also, below you will find stories about the importance of...

Read more
iCubate Weekly Digest April 17, 2020

iCubate Weekly Digest April 17, 2020

All of us are working to flatten the curve during the fight against coronavirus and taking proactive, protective steps plays a major part in these efforts. As iCubate continues to deliver iC-Systems and diagnostic assays to organizations around the world, it is done with the safety of our team in...

Read more
iCubate Weekly Digest April 7, 2020

iCubate Weekly Digest April 7, 2020

As the nation and the world continues to adjust to the impact of COVID-19, the team at iCubate is working to offer diagnostic solutions. We encourage each of you to follow the guidance provided by the CDC and other trusted voices. Below is the latest information from the CDC on face coverings. Additionally,...

Read more
COVID-19 FAQ

COVID-19 FAQ

When person-to-person spread has occurred with other coronavirus types such as MERS and SARS, it is thought to have happened mainly via respiratory droplets produced when an infected person coughs or sneezes, similar to how influenza and other respiratory pathogens spread. Spread of SARS and MERS between people has generally...

Read more
iCUBATE® PRESENTS DATA ON THE IC-MYCO ASSAY AT THE AMERICAN ASSOCIATION OF CLINICAL CHEMISTRY MEETING

iCUBATE® PRESENTS DATA ON THE IC-MYCO ASSAY AT THE AMERICAN ASSOCIATION OF CLINICAL CHEMISTRY MEETING

THE iC-MYCO ASSAY WAS RECENTLY DESIGNATED “BREAKTHROUGH DEVICE” BY FDA ANAHEIM, CA, August 8, 2019 – At the 71st Annual American Association of Clinical Chemistry Scientific Meeting and Clinical Lab Expo, iCubate®, a provider of molecular diagnostic solutions for infectious disease detection, presented data on the company’s iC-Myco Assay. iCubate’s...

Read more
CEO Corner

CEO Corner

HUNTSVILLE, AL, July 22, 2019 – It has been a month of milestones for iCubate with our iC-GN Assay™ receiving CE IVD Marking and US FDA clearance. We look forward to talking about this and what is next for iCubate at the AACC conference in August. iCubate now provides a...

Read more
iCUBATE® EARNS FDA CLEARANCE FOR LATEST ASSAY

iCUBATE® EARNS FDA CLEARANCE FOR LATEST ASSAY

NOW PROVIDING U.S. CLINICAL LABORATORIES A COMPREHENSIVE DETECTION SOLUTION IN THE BATTLE AGAINST BLOODSTREAM INFECTIONS AND SUBSEQUENT SEPSIS   HUNTSVILLE, AL, July 12, 2019 – iCubate®, provider of accurate and affordable syndromic test systems generating actionable results to healthcare providers, announced today that it has obtained U.S. Food and Drug...

Read more